TINAVI logo

TINAVI

TINAVI, based in Beijing, China, makes the TiRobot orthopedic surgical robot, which guides screw and instrument placement in spine, trauma, and joint replacement surgery. It reported 2025 revenue of 279 million yuan, about 39 million dollars, and a net loss of 183 million yuan.2,3,6

Robotics Reviewed Editorial TeamUpdated November 9, 2026tinavi.com

Our take

TiRobot is China's leading orthopedic surgical robot and one of few that covers spine, trauma, and joint replacement on one machine. TINAVI reports more than 180,000 cases at more than 200 hospitals across 31 provinces by mid 2026.2,4

Outside China it is an early option. Its CE MDR certificate covers spinal navigation and positioning, it publishes no prices, and it lost 183 million yuan in 2025 on 279 million yuan of revenue.4,6

Scores by criterion

TINAVI scores out of 10
Pricing transparency3.0
Product maturity7.5
Deployment evidence7.5
Company durability5.5
Ease of integration6.0
Overall score (average of the five)5.9

Pricing transparency, 3.0: TINAVI publishes no prices for TiRobot or its instruments.3

Product maturity, 7.5: TINAVI was founded in 2005, received China's first orthopedic robot registration in 2010, launched TiRobot II in 2021, and holds more than 300 patents.1,2

Deployment evidence, 7.5: TINAVI reports more than 180,000 TiRobot cases at more than 200 medical institutions in 31 provinces by the end of the second quarter of 2026. Nearly all of that use is in China.2

Company durability, 5.5: TINAVI has been listed on the Shanghai STAR Market since 2020. Its 2025 revenue rose 55.9% to 279 million yuan, but its net loss widened to 183 million yuan from 121 million yuan.5,6

Ease of integration, 6.0: TiRobot II adds integrated arm control, one-button screw selection, a C-arm tracker, and real-time planning to simplify the workflow. English product documentation is thin, and its EU clearance covers spine use.3,4

Each criterion is defined on our methodology page.

Who uses TINAVI and what it's for

The buyer is a hospital in China, or a European spine center, that wants one robot for spine, pelvis, femoral neck, and joint procedures rather than separate systems.2,4

Buyers should compare it with Stryker's Mako, Globus Medical's ExcelsiusGPS, THINK Surgical's TMINI, and eCential Robotics' spine platform.3

TiRobot and TiRobot II

TiRobot covers spine surgery at all levels from cervical to sacral, trauma surgery in the pelvis, acetabulum, and limbs, and joint replacement. TINAVI says it is the only robot that handles all three fields on one device.2,4

TiRobot II, the latest system, adds a multi-function arm, a sterile surgical display, and a simplified workflow, and TINAVI also sells a 5G remote surgery system and robot instruments.3,1

Clinical use

TINAVI's case count grew from more than 50,000 in 2023 and 90,000 in 2024 to more than 150,000 by the end of 2025 and more than 180,000 by mid 2026.1,2

TINAVI signed a commercial and research agreement with Johnson & Johnson Medical in 2019 and a strategic agreement with Shandong Weigao in 2022.1,5

Pricing

TINAVI does not publish prices. Buyers should ask for the system price, per-case instrument costs, and service terms, and confirm which indications are cleared in their country.3,4

Company and revenue

TINAVI was founded in 2005 and is headquartered in Beijing, China. Chairman Zhang Songgen was its largest listed shareholder at the end of 2025 with 16.7%.1,6

Our dollar figure converts 279 million yuan at about 7.2 yuan per dollar.6

Competitive landscape

Which of these companies scores best, and who is each one built for?Hover over or tap a logo for details.
Top rated, for smaller operationsTop rated, for large enterprisesLower score, for smaller operationsLower score, for large enterprisesNot yet reviewed45678910Review Score← Smaller operationsLarge enterprises →Who it's built for5.97.56.86.1
TINAVI and its competitors
CompanyProductPricing modelDeployment evidenceWhere TINAVI wins or loses
TINAVITiRobot II for spine, trauma, and joint surgery3Quote; no prices published3More than 180,000 cases at more than 200 hospitals2Broad indications; mostly China; loss-making
Stryker Mako SmartRoboticsMako 4 with CT planning and AccuStop haptics8Quote; no prices published8More than two million procedures in more than 45 countries7Mako wins on the largest base of robotic joint procedures. TINAVI wins on one robot for spine, trauma, and joint cases.
Globus Medical ExcelsiusGPSRigid arm plus full navigation, CT or fluoroscopy11Quote; spec sheet by request11141.0 million dollars of enabling technology sales in 202510ExcelsiusGPS wins on rigid trajectory guidance with flexible imaging. TINAVI wins on one robot for spine, trauma, and joint cases.
THINK Surgical TMINIHandheld, wireless knee robot with TPLAN planning12Quote; demo by request125,000 procedures by May 202612TMINI wins on a small knee robot open to many implants. TINAVI wins on one robot for spine, trauma, and joint cases.
eCential RoboticsImaging, navigation, and robotics in one platform13Quote; demo by request13More than 3,500 surgeries13eCential wins on built-in 3D imaging with any brand of screw. TINAVI wins on one robot for spine, trauma, and joint cases.
CurexoCUVIS-joint fully automatic knee robot, CUVIS-spine navigation, MorningWalk14Quote14More than 100 CUVIS-joint installs; Korea, India, US, Australia launches15Curexo wins on fully automatic bone cutting on an open implant platform. TINAVI wins on trauma and spine coverage at a lower price in China.

Limits

No published price.3

Loss-making: a 183 million yuan net loss in 2025.6

EU certification covers spine navigation and positioning only.4

What customers say

Where it helps

One TiRobot covers spine, trauma, and joint replacement procedures.2

Where it falls short

English product information on TINAVI's site is limited.3

Leadership

TINAVI does not publish a leadership team page in English. Its chairman, Zhang Songgen, was elected vice chairman of the medical robot branch of the Chinese Society of Biomedical Engineering and was TINAVI's largest listed shareholder at the end of 2025.1,6

    Sources